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Background: Danazol, a drug extensively used in the management of hereditary angioedema due to C1 inhibitor
deficiency (C1-INH-HAE), has various side effects. This study investigated the virilizing actions of this drug in 31
danazol-treated female patients with HAE-C1-INH. We compared our findings with those of healthy controls and
with literature data.
Methods: The patients were interviewed individually about the type and severity of the virilizing effects, as well as
about their satisfaction with danazol therapy.
Results: The average duration of danazol treatment was 10.31 years [2 to 23] and its mean daily dose was
131.7 mg [33 to 200]. The most common adverse effects were hirsutism (n = 14), weight gain (n = 13), and
menstrual disturbances (n = 8). The severity of danazol adverse effects did not differ by duration of treatment or by
daily drug dose. The mean level of patient satisfaction with the treatment was high. The comparison of age-matched
healthy controls and of HAE-C1-INH patients receiving danazol did not demonstrate a statistically higher incidence of
any of the monitored symptoms in the danazol group.
Conclusions: Our findings indicate that long-term danazol treatment – using the lowest effective dose – has only a
mild virilizing effect.
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Hereditary angioedema due to C1 inhibitor deficiency
(C1-INH-HAE) is an autosomal dominant disorder; a
form of bradykinin-mediated angioedema. It is charac-
terized by recurrent, subcutaneous, and/or submucosal
edema-formation. The clinical symptoms show inter- and
intraindividual variation [1]. Women with C1-INH-HAE
are more likely to experience symptoms than are men [2].
Female sex hormones – estrogens, in particular – affect
the synthesis of many proteins influencing the activation
of the kinin-kallikrein system [3,4]. The management
of female patients with C1-INH-HAE is similar to that of
males. It comprises two stages: 1) the acute treatment of
attacks, and 2) prophylaxis [3]. As regards medicinal prod-
ucts for long-term prophylaxis (such as antifibrinolytics,* Correspondence: farkas.henriette@med.semmelweis-univ.hu
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the use of attenuated androgens in women with HAE
raises a number of concerns [5]. Although the precise
mode of action of AAs is unknown, these agents are
thought to increase C1-INH level by stimulating hep-
atic synthesis, as well as by enhancing the expression
of C1-INH mRNA in peripheral blood mononuclear
cells [6]. The AAs also may have a potentiating effect
on Aminopeptidase P, which is involved in kinin in-
activation [7]. While AAs are not intended for the treat-
ment of C1-INH-HAE, these drugs have found their way
into clinical practice through empirical use. AAs are ef-
fective as prophylaxis to reduce the frequency and severity
of edematous attacks in C1-INH-HAE [8]; however, their
benefits should be weighed against their risks before
prescription. Major side effects of AAs include hepato-
toxicity, altered/pro-atherogenic lipid profile, stimulated
erythropoesis, androgen-induced premature closure of thetd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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like effect [9]. The latter is the primary concern in the
management of female patients. Reviewing the literature,
we found only a few studies evaluating the virilizing/
androgen-like effects of AAs in female patients with
C1-INH-HAE [10-14]. These studies did not explore
systematically the whole range of virilizing side effects,
and even those that did, failed to analyze male and fe-
male patients separately – or lacked a control group.
Therefore, we investigated and evaluated the frequency
and severity of the possible virilizing effects of AAs in
female patients with C1-INH-HAE, as well as compared
our findings with the results of healthy controls and with
literature data. Our study did not analyze either thera-
peutic efficacy, or the spectrum of other adverse events
(such as altered lipid profile, hepatotoxicity, etc.), as we
have published papers on these topics earlier [15-17].
Patients and methods
Patients
All (31 of our 75) female patients with C1-INH-HAE
(median age: 49 years; min: 20 max: 70), who were tak-
ing danazol for long-term prophylaxis participated in
this survey. All subjects had been diagnosed and receiv-
ing regular follow-up care at the Hungarian Angioedema
Center. In each patient, C1-INH-HAE was diagnosed ac-
cording to the accepted clinical and laboratory criteria
(positive family history, clinical symptoms of angioedema,
low functional C1-INH level, low C4, normal C1q) [1]. At
the time of the study, 16 patients with C1-INH-HAE were
postmenopausal, one patient was taking an oral contra-
ceptive (desogestrel).
After diagnosis, the patients attended follow-up visits
at least once a year. A laboratory screen (including com-
plete blood count, clinical chemistry, serum lipid profile,
and liver function), abdominal sonography, and physical
examination were performed on these occasions. Body
weight was recorded along with the current drug regimen
and dose administered, as well as the side effects experi-
enced by the patients.
The control group consisted of 41 healthy and age-
matched female subjects (median age: 48 years; min: 32
max: 63). 22 of 41 were postmenopausal, 9 of them lon-
ger than 5 years, and 7 women were taking an estrogen-
containing oral contraceptive. All had been referred for
routine medical check-up, and volunteered for the study
by giving informed consent. The healthy controls did
not have any known disease (C1-INH deficiency was ex-
cluded by complement testing), or receive medicinal
products at the time of blood sampling.
Methods
In our retrospective study, we compiled a list of the viriliz-
ing adverse effects of danazol by interviewing the patients,and reviewing the literature. We identified the following:
menstrual disturbances (spotting, disruption of the men-
strual cycle), altered libido, voice change, body hair growth
(evaluated in 7 body regions by self-examination: upper
lip, chin, chest, back, abdomen, thighs and legs), hypertro-
phy of the clitoris, increased muscle mass, reduction of
breast size, acne and oily skin, weight gain, water reten-
tion, hair loss, psychological abnormalities (depression, ag-
gressive behavior), flushing, sweating. At the follow-up
visits, we provided patients with the list of all possible viri-
lizing side effects and asked them to mark every symptom
or sequel they had experienced during danazol therapy
and rate their severity using the following scores: 0 = none,
1 =mild, 2 =moderate, 3 = severe. Furthermore, the pa-
tients were asked to rate the overall severity of the adverse
effects (considering all types aggregately). Patient satis-
faction with danazol therapy (weighing adverse effects
against benefits) was rated on a Visual Analog Scale (VAS;
100 mm per scale). The daily dose of danazol was deter-
mined as the mean of the daily doses received during the
course of therapy. During prophylaxis, we placed em-
phasis on administering the lowest effective dose. The 41
age-matched, healthy controls also completed the survey
on the adverse events they had experienced during the last
five years. The study was approved by the institutional re-
view board of Semmelweis University of Budapest, and
informed consent was obtained in accordance with the
Declaration of Helsinki.
We used GraphPad Prism 6 software for statistical ana-
lysis. Spearman’s correlation tests were applied to evaluate
correlations. Chi-squared statistics were used to detect
any significant difference among the study parameters
of the HAE patients and those of the healthy controls.
All the statistical analyses were two-tailed, and p < 0.05
was considered to represent a significant difference, or
correlation.
Results and discussion
Thirty-one female patients with C1-INH-HAE took da-
nazol for long-term prophylaxis. The average dose was
131.7 (min: 50, max: 200) mg/day. The mean duration
of pre-existing danazol treatment was 10.31 (min.: 2,
max.: 23) years.
The patients experienced on average 2.9 out of the 12
monitored virilizing adverse effects. Five patients did not
experience any side effect whatsoever. Hirsutism (n = 14,
42%), weight gain (n = 13, 39%, 10 kilograms on average),
and menstrual disturbances (n = 8, 26%) were the virili-
zing effects most commonly noted by the C1-INH-HAE
patients. Table 1 shows our results in comparison with
literature data, whereas Figure 1 presents the mean se-
verity scores of the individual adverse effects. The pa-
tients rated the majority of these as mild (0 or 1). One
patient assigned a score of 3 to weight gain experienced
Table 1 Comparison of the virilizing adverse effects of AAs among different studies
Gelfand [7] Zurlo [8] Cicardi [9] Sloane [10] Bork [11] Our study population
Patients Controls
N° of patients 5 60 28 (D + S) 13 (S) 51/118* 31 41
MENSTRUAL DISTURBANCES 100% 79% 50% (D)/ 18% (S) 23% 76% 26% 38%
ALTERED LIBIDO 10% 8% 3%* 13% 22%
VOICE CHANGE 8% 8% 14%* 19% 10%
HAIR GROWTH 12% 19* 42% 37%
CLITORIS ENLARGEMENT 12% 3% 0%
INCREASED MUSCLE MASS 2% 3%* 13% 7%
BREAST SIZE 12% 16% n.a.#
ACNE/OILY SKIN 8% 8% 9* 19% 12%
WEIGHT GAIN 100% 60% 28% (D)/17% (S) 1% 42%* 39% 59%
WATER RETENTION 2% 6% 29%†
HAIR LOSS 18% 19% 27%
PSYCHOLOGICAL ABNORMALITIES 2% 0% 11%* 16% 46%†
Discontinuation/continuation of
danazol therapy












Although we would have preferred specifying the absolute numbers of patients, this was not feasible, because not all the authors provided this information.
Therefore, all values are expressed as percentages, for the sake of comparability. References are reported in brackets.
D = danazol, S = stanazolol, * = total HAE population (The properties were evaluated both in males and in females), † = p < 0.05, #n.a = Half of the women did not
answer this one, or gave information on the elasticity of their breasts.
Figure 1 The severity scores of each and all adverse events, ranked by severity on a 3-grade scale.
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growth and menstrual disturbances with a score of 2.
The mean score reflecting the overall severity of the
side effects was 0.7 (min.: 0, max.: 3; see Figure 1). The
Spearman’s test did not reveal a significant correlation
between the overall severity score of adverse effects and
the duration of treatment (p = 0.599), or the daily dose
of danazol (p = 0.204).
Analyzing the most common and most severe adverse
effect separately with Spearman’s test, we could not de-
tect any significant correlation between the patients’ BMI
and danazol dose (p = 0.671). We found a significant, posi-
tive relationship between the patients’ BMI and the dur-
ation of treatment (p = 0.031). The change in body weight
did not correlate with either the dose (p = 0.818), or with
the duration of danazol treatment. Menstrual disturbances
occurred in 8 patients. Six of these patients discontinued
danazol (because they wanted to have a child) and their
menstrual cycles became regular again.
The mean score (VAS, 100 mm per scale) of patient sat-
isfaction was 84 (min.: 30, max.: 100). None of the patients
discontinued danazol treatment due to virilizing adverse
events. The Pearson’s test did not detect any significant
correlation between patient satisfaction with danazol and
the duration of treatment, or the daily drug dose.
Comparing female HAE patients with their age-matched,
healthy controls, we did not detect a statistically signifi-
cant difference in the majority of the study parameters.
Water retention and psychological abnormalities were
exceptions, as their incidence was statistically higher in
the control group than among the patients (29% vs. 6%,
p = 0.0177; and 46% vs. 16%, p = 0.011, respectively).
Our findings indicate that long-term treatment with
the lowest effective dose of danazol has only a mild viri-
lizing effect, because the patients experienced three on
average out of the 12 monitored adverse events. The se-
verity of the virilizing adverse effects (scored in the range
from 0 to 3) was below 0.5 in all instances, and the overall
score was as low as 0.7 for the whole study population. Of
note, the mean age of our patients was in the age range
when menopause usually occurs – thus, these adverse ef-
fects might even have resulted from spontaneous pro-
androgenic events. In agreement with literature data, the
most common adverse effects included hirsutism, weight
gain, and menstrual disturbances (Table 1). Weight gain
has not yet been demonstrated to be a direct consequence
of treatment with AAs, although we found that the longer
the duration of treatment, the higher the body mass index
of the female patients. However, the magnitude of the
change in body weight did not correlate with any of the
above parameters. Hirsutism occurred more commonly
than in the other studies, but its frequency did not exceed
that seen in the Hungarian general population, as well as
it was of mild severity. Menstruation disturbances werecommon but reversible and resolved after AAs had been
discontinued; this is also in agreement with the observa-
tions published in the literature.
Many authors emphasized that these adverse effects
are dose-related [14,18,19]. We could not demonstrate
this relationship in our study, because our patients were
taking relatively low doses. Nevertheless, this observa-
tion further supports the practice of administering the
lowest effective dose to prevent side effects. Discontinu-
ing prophylactic treatment because of the virilizing effect
of danazol was not necessary in any of our patients. This
matches the experience of other authors, who have found
that only a small proportion of patients had to stop taking
danazol due to its virilizing effect [12-14].
The reports available on the virilizing adverse effects
of danazol indicate that these events commonly occur in
women taking this medicinal product. However, this does
not necessarily mean that these side effects are severe. In
our study population, the severity scores of the adverse
events consistently remained below the ‘mild’ rating –
possibly, because we had administered average or lower
doses. To date, the studies published in the literature
reported the incidence of adverse events without ana-
lyzing their severity. This might explain the incongruity
between the abundance of virilizing adverse effects attri-
buted to danazol, and the small number of patients who
discontinue treatment because of these events (mostly
those receiving higher doses). Further, a causal relation-
ship between treatment with danazol and the occurrence
of virilizing adverse effects cannot be established with cer-
tainty, because the difference compared with the healthy
population was not statistically significant. In view of the
patients’ age, these symptoms might even be attributable
to the menopause.
Conclusion
The virilizing effects of AAs are mild at the lowest ef-
fective dose not to exceed 200 mg. State-of-the-art medi-
cinal products with known mechanisms of action, as well
as with confirmed efficacy and safety have become avail-
able (such as plasma-derived nanofiltered C1-INH con-
centrate – Cinryze) [20]. Other alternatives (for example
recombinant human C1-INH) for prophylaxis are also
under investigation [21]. Notwithstanding this, treatment
with attenuated androgens is considered an alternative for
prophylaxis. These agents are administered by the oral
route, which is convenient for the patients and economical
for the health service provider. The occurrence of adverse
effects can be prevented or their timely recognition is feas-
ible through regular follow-up at least once a year [22,23].
Further, novel therapeutic options are not yet available in
many countries. Therefore, abandoning treatment with
AAs is not yet possible, because in many countries, these
drugs offer the only therapeutic option for severe cases.
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